Having trouble viewing this email? View in your browser.
ESCMID Logo

22 October 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

ECCMID 2020 is approaching: don’t miss the opportunity to enjoy Prof. Elizabeth Murchison’s Keynote Lecture. Register now!

Elizabeth Murchison is Professor of Comparative Oncology and Genetics at the University of Cambridge, Department of Veterinary Medicine. Her laboratory, the Transmissible Cancer Group, studies the genetics, evolution and host interactions of clonally transmissible cancers in dogs and Tasmanian devils. We are extremely pleased to have Prof. Murchison as a keynote speaker at ECCMID 2020! The title of her lecture will be “Transmissible or infectious tumours: breaking the cancer paradigm

Visit the ECCMID 2020 website to find out about our outstanding keynote speakers and to take advantage of early registration discounts!

› Read more

ECCMID Programme Book and Associated Grants

If you wish to have a printed ECCMID Programme Guide, don’t forget to add one when you register for ECCMID. As for 2019, the printed guide is available for a €20 donation.

This initiative will help to save over 10 Tonnes of paper waste at this year’s ECCMID. The money collected from the sale of programme books will be used to support the costs of delegates that otherwise would not be able to attend ECCMID. Find out more about the Programme Book grant initiative on the ECCMID Website.

› Read more

ECDC Traineeships now open

The European Centre for Disease Prevention and Control (ECDC) offers a traineeship programme targeted towards recent university graduates who are at the beginning of a new professional career. The purpose of the programme is to provide trainees with an understanding of the Centre and its role within the activities of the European Union while also providing an opportunity to acquire practical knowledge and professional experience.

The duration of traineeships 2019 is between a minimum of five months and a maximum of nine months.

Applications can be made on the ECDC Website.

› Read more
 

EUCAST News – Breakpoint utilization and temocillin consultation

Updated statistics on the popularity of the EUCAST website and breakpoint tables have been announced by EUCAST.

Consultation is also open for the proposed EUCAST clinical breakpoints for temocillin, with comments being welcomed until November 8, 2020.

› Read more
 

ESGAP - Grants for the 5th ESGAP antibiotics course

ESGAP will organize its 5th European antibiotics course in Valencia, Spain from Thursday, March 26th to Saturday, March 28th 2020. In an intensive three-day program, clinical experts cover the basics of antibiotic therapy, and will discuss the rationale behind the antibiotic treatment regimens of the most relevant infections for medical specialists.

For further details on the course see: www.antibioticscourse.com.

For this edition, ESGAP offers ten participation grants. Recipients of the ESGAP-grants will be offered registration at the discounted rate of €75. Note that the grant does not cover travel or stay. In awarding the grants preference will be given to (1) ESCMID-members, (2) doctors at the beginning of their career (<40 years). A geographical and gender-balance will be pursued.

To apply for a grant, please send a short motivation letter (max 200 words) and curriculum (max 1 A4 sheet) to the ESGAP secretary Tomislav Kostyanev: Tomislav.Kostyanev@uantwerpen.be 

The deadline to apply for a grant is December 1st 2019.

› Read more
 

Epidemiology and determinant of outcomes of hospital acquired Blood Stream Infections in the intensive care (Eurobact II): collaborate now!

Eurobact II is a multinational cohort study launched by the ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) in collaboration with the infection section of the European Society of Intensive Care Medicine (ESICM). This dual society collaborative aims at updating the epidemiology and the determinant of outcomes of hospital acquired blood stream infections treated in the ICU.

With National coordinators in 53 countries and already 408 registered ICUs it is the opportunity to contribute to the largest study of its kind and understanding how pathogen, infection, patient and treatment characteristics may influence the outcomes of patients with severe infections in the ICU.
  
Data collection only, a streamlined CRF and 10 cases or 3 months for each ICU the amount of work required from each site is minimal.

Please sign up here to collaborate in the study from the webpage
or contact eurobact@eurobact.org for more information on how to become a collaborator

› Read more
 

Guidance Reminder: ESCMID call for clinical practice guidelines projects 2019

The ESCMID Guideline Subcommittee invites ESCMID members and ESCMID study groups to submit proposals for clinical practice guidelines projects in the 4 priority topics identified by the first global survey among stakeholders in the infectious diseases, clinical microbiology and infection control field across the world. The (broad) topics are:

  • Antimicrobial stewardship
  • Diagnosis and management of influenza
  • Surgical prophylaxis and infection control mean, in patients colonised by MDR pathogens before surgery
  • Diagnostic and treatment of non-hospitalized Community Acquired Pneumonia

Full details can be found in the call text and in the newly released ESCMID manual for guidance documents.

Deadline for project proposals is October 31st 2019
  
For any questions, please write to guidancedocuments@escmid.org.

› Read more
 

CMI Highlight: Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial

DR. Cranendonk et al, investigate whether 6 days of antibiotic treatment duration is non-inferior to 12 days in patients hospitalised for cellulitis. This multicentre, randomised, double-blind, placebo-controlled, non-inferiority trial enrolled adult patients hospitalised for severe cellulitis who were treated with intravenous flucloxacillin. At day 6 participants with symptom improvement who were afebrile were randomised between an additional 6 days of oral flucloxacillin or placebo in a 1:1 ratio, stratified for diabetes and hospital. The primary outcome was cure by day 14, without relapse by day 28. Secondary outcomes included a modified cure assessment and relapse rate by day 90.

Between August 2014 and June 2017, 151 of 248 included participants were randomised. The intention-to-treat population consisted of 76 and 73 participants allocated to 12 and 6 days antibiotic therapy, respectively (mean age 62 years, 67% males, 24% diabetics). 38/76 (50.0%) and 36/73 (49.3%) were cured in the 12- and 6-day groups (ARR 0.7 percentage points, 95% CI: -15.0 to 16.3). Cure rates were 56/76 (73.7%) and 49/73 (67.1%) with the modified cure assessment (ARR 6.6, 95% CI: -8.0 to 20.8). After initial cure without relapse, day 90 relapse rates were higher in the 6-day group (6% vs 24%, p<0.05).

The authors concluded that given the wide confidence intervals, we can neither confirm nor refute our hypothesis that 6 days of therapy is non-inferior to 12 days of therapy. However, a 6-day course resulted in significantly more frequent relapses by day 90. These findings require confirmation in future studies.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.